The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Doggrell Henry Patton since 2006.
The trader's CIK number is 1276242.
At the time of the last reporting, Doggrell Henry Patton was the Vice President and S of Oncternal Therapeutics, Inc.. (stock ticker symbol ONCT).
Also see all insider trading activities at Oncternal Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | GTXI | 0 | $0 | 12,316 | $197,174 | 0 | $0 |
| 2015 | GTXI | 25,477 | $20,381 | 0 | $0 | 0 | $0 |
| 2014 | GTXI | 10,000 | $9,750 | 0 | $0 | 0 | $0 |
| 2011 | GTXI | 7,500 | $17,452 | 0 | $0 | 0 | $0 |
| 2008 | GTXI | 0 | $0 | 34,669 | $600,113 | 20,000 | $245,799 |
| 2007 | GTXI | 0 | $0 | 0 | $0 | 10,000 | $147,700 |
| 2006 | GTXI | 0 | $0 | 0 | $0 | 5,000 | $33,900 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-06-20 | GTXI | Sale | 7,351 | 19.00 | 139,705 |
| 2018-01-05 | GTXI | Sale | 4,965 | 11.57 | 57,469 |
| 2015-05-08 | GTXI | Buy | 25,477 | .80 | 20,381 |
| 2014-08-08 | GTXI | Buy | 10,000 | .97 | 9,750 |
| 2011-03-02 | GTXI | Buy | 7,500 | 2.33 | 17,452 |
| 2008-12-10 | GTXI | Sale | 4,169 | 17.04 | 71,018 |
| 2008-09-08 | GTXI | Sale | 500 | 18.43 | 9,217 |
| 2008-08-06 | GTXI | Sale | 10,000 | 18.95 | 189,549 |
| 2008-08-06 | GTXI | Sale | 10,000 | 18.95 | 189,549 |
| 2008-05-27 | GTXI | Sale | 10,000 | 14.08 | 140,780 |
| 2008-02-22 | GTXI | Option Ex | 20,000 | 12.29 | 245,799 |
| 2007-07-24 | GTXI | Option Ex | 10,000 | 14.77 | 147,700 |
| 2006-05-12 | GTXI | Option Ex | 5,000 | 6.78 | 33,900 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Doggrell Henry Patton (Vice President and S of Oncternal Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.